Labcorp Holdings LH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharma Laboratory Services | $780.6M-1.6% | $793M-0.8% | $799.1M+1.8% | $784.8M+8.8% | $721.3M-6.0% | |
| Diagnostics | $2.76B+1.2% | $2.73B-1.5% | $2.77B+0.8% | $2.75B+4.5% | $2.63B+1.7% | |
| Operating Income by Business | ||||||
| Biopharma Laboratory Services | $120.7M-11.3% | $136.1M+3.0% | $132.2M+7.2% | $123.3M+15.3% | $106.9M-18.2% | |
| Corporate Segment | -$116.6M-15.8% | -$100.7M+8.4% | -$109.9M+21.0% | -$139.2M-5.1% | -$132.4M+30.0% | |
| Diagnostics | $458.7M+9.4% | $419.2M-6.9% | $450.4M-6.7% | $482.8M+12.9% | $427.5M+18.9% | |
| Percent of Revenue Contributed by Business | ||||||
| Biopharma Laboratory Services | 22%— | —— | 22%0.0pp | 22%0.0pp | 22%— | |
| Diagnostics | 78%— | —— | 78%0.0pp | 78%0.0pp | 78%— | |
| Other Cost and Expense, Operating by Business | ||||||
| Biopharma Laboratory Services | $89.7M-1.2% | $90.8M-11.7% | $102.8M+1.6% | $101.2M+12.4% | $90M-4.7% | |
| Diagnostics | $438M-1.8% | $446M-3.6% | $462.8M+1.9% | $454.2M+5.6% | $430.2M+0.8% | |
| Goodwill acquired, excluding measurement period adjustments by Business | ||||||
| Biopharma Laboratory Services | $0— | $0— | $0— | —— | —— | |
| Diagnostics | $146.6M+35.9% | $107.9M-22.3% | $138.8M— | —— | —— | |
| Accounts Receivable, before Allowance for Credit Loss by Business | ||||||
| Biopharma Laboratory Services | $808.4M+2.2% | $791.2M+5.9% | $747M-0.4% | $750.1M-1.1% | $758.6M+4.0% | |
| Diagnostics | $1.51B+12.2% | $1.35B-3.6% | $1.4B-0.8% | $1.41B+0.5% | $1.4B+11.4% | |
| Foreign currency impact and other adjustments to goodwill by Business | ||||||
| Biopharma Laboratory Services | -$9M-305% | $4.4M— | —— | —— | —— | |
| Diagnostics | $28.1M— | —— | $27.3M— | —— | —— | |
| Labor and Related Expense by Business | ||||||
| Biopharma Laboratory Services | $309.3M-2.1% | $315.8M+0.6% | $313.8M+3.8% | $302.3M+4.3% | $289.7M-2.2% | |
| Diagnostics | $1.19B-1.7% | $1.21B+0.6% | $1.2B+3.9% | $1.16B+2.8% | $1.12B-3.5% | |
| Supplies Expense by Business | ||||||
| Biopharma Laboratory Services | $121.5M+3.8% | $117.1M-2.0% | $119.5M-8.6% | $130.8M+17.7% | $111.1M-9.1% | |
| Diagnostics | $613.5M+4.0% | $589.7M+0.1% | $589.4M-0.3% | $591.3M+0.8% | $586.6M+3.5% | |
| Goodwill by Business | ||||||
| Biopharma Laboratory Services | $1.35B-0.7% | $1.35B+0.3% | $1.35B-2.5% | $1.39B— | —— | |
| Diagnostics | $5.61B+3.2% | $5.43B+1.9% | $5.33B+3.2% | $5.17B— | —— | |
| Depreciation by Business | ||||||
| Biopharma Laboratory Services | $28.6M-2.7% | $29.4M+1.4% | $29M0.0% | $29M+1.4% | $28.6M-3.4% | |
| Diagnostics | $63.8M-2.3% | $65.3M-1.7% | $66.4M+1.5% | $65.4M+6.0% | $61.7M-10.7% | |
| Percent of Revenue Contributed by Geography | ||||||
| Europe | 10%— | —— | 9%0.0pp | 9%0.0pp | 9%— | |
| North America | 86%— | —— | 87%0.0pp | 87%0.0pp | 87%— | |
| Other countries | 4%— | —— | 4%0.0pp | 4%0.0pp | 4%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Labcorp Holdings break its business down?
- Labcorp Holdings (LH) reports revenue by business across 2 parts — Biopharma Laboratory Services and Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Labcorp Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Labcorp Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
